Interim Safety Analysis or Re-Screening [Design Issues]

posted by professionalr – India, 2025-01-09 23:56 (106 d 17:13 ago) – Posting: # 24336
Views: 1,029

Hi all,

We are planning to conduct a bioequivalence study for submission in Egypt. The molecules of interest necessitate a washout period of approximately three months in a crossover design. Should we perform re-screening/interim safety analysis before the dosing of Period II?


Edit: Category changed; see also this post #1[Helmut]

Thanks,
RP.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
21 visitors (0 registered, 21 guests [including 3 identified bots]).
Forum time: 18:10 CEST (Europe/Vienna)

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5